Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020136209 - PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER

Publication Number WO/2020/136209
Publication Date 02.07.2020
International Application No. PCT/EP2019/087029
International Filing Date 24.12.2019
IPC
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
CPC
A61K 2039/555
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
A61K 2039/55533
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
555characterised by a specific combination antigen/adjuvant
55511Organic adjuvants
55522Cytokines; Lymphokines; Interferons
55527Interleukins
55533IL-2
A61K 2039/6093
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
60characteristics by the carrier linked to the antigen
6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
A61K 2039/62
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
62characterised by the link between antigen and carrier
A61K 2039/64
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
64characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
A61K 2039/645
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
64characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
645Dendrimers; Multiple antigen peptides
Applicants
  • NEOGAP THERAPEUTICS AB [SE]/[SE]
Inventors
  • GRONLUND, Hans
Agents
  • ABEL & IMRAY
Priority Data
1821205.024.12.2018GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) PHAGOCYTISABLE PARTICLE FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCER
(FR) PARTICULE PHAGOCYTABLE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT OU LA PROPHYLAXIE DU CANCER
Abstract
(EN)
The invention provides a phagocytosable particle for use in the treatment or prophylaxis of cancer in a subject, wherein the phagocytosable particle comprises a core and a neoantigenic construct tightly associated to the core, and wherein the neoantigenic construct comprises a neoepitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in the subject, wherein the part of the protein or peptide has at least one somatic mutated amino acid. The invention also relates to injectable pharmaceutical compositions for use in the treatment or prophylaxis of cancer.
(FR)
L'invention concerne une particule phagocytable destinée à être utilisée dans le traitement ou la prophylaxie du cancer chez un sujet, la particule phagocytable comprenant un noyau et une construction néo-antigénique étroitement associée au noyau, et la construction néo-antigénique comprenant un peptide néo-épitope ayant une séquence d'acides aminés correspondant à une séquence d'acides aminés d'une partie d'une protéine ou d'un peptide connu ou suspecté d'être exprimé par une cellule cancéreuse chez le sujet, la partie de la protéine ou du peptide ayant au moins un acide aminé présentant une mutation somatique. L'invention concerne également des compositions pharmaceutiques injectables destinées à être utilisées dans le traitement ou la prophylaxie du cancer.
Latest bibliographic data on file with the International Bureau